Synapse Open Synapse
Biology

3 takeaways from a European obesity scientific meeting

BioPharma Dive · · 3 min read

Eli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their contenders.

Latest from BioPharma Dive